Zyflamend induces apoptosis in pancreatic cancer cells via modulation of the JNK pathway.

ABSTRACT:

Background

Current pharmacological therapies and treatments targeting pancreatic neuroendocrine tumors (PNETs) have proven ineffective, far too often. Therefore, there is an urgent need for alternative therapeutic approaches. Zyflamend, a combination of anti-inflammatory herbal extracts, that has proven to be effective in various in vitro and in vivo cancer platforms, shows promise. However, its effects on pancreatic cancer, in particular, remain largely unexplored.

Methods

In the current study, we investigated the effects of Zyflamend on the survival of beta-TC-6 pancreatic insulinoma cells (β-TC6) and conducted a detailed analysis of the underlying molecular mechanisms.

Results

Herein, we demonstrate that Zyflamend treatment decreased cell proliferation in a dose-de

SUBMITTER: Puckett DL 

PROVIDER: S-EPMC7427957 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature